drugset / Trial / NCT05919329
Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy
Phase 4
Recruiting
80 enrolled
OHSU Knight Cancer Institute
Oregon Health and Science University · collabProgenics Pharmaceuticals, Inc. · collab
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
This clinical trial investigates the change in prostate-specific membrane antigen (PSMA) expression in response to hormonal therapy in both, Castration Sensitive Prostate Cancer (CSPC) and Castration Resistant Prostate Cancer (CRPC), and whether this change in PSMA expression changes tumor staging after therapy initiation. Understanding these effects can help define the best timing to perform the PSMA positron emission tomography (PET) relative to the start of therapy.
Timeline
- Start
- 2024-06-25
- Primary completion
- 2028-09-01
- Completion
- 2030-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DCFPyL | Small molecule | — | Intravenous |